Bowen Hanes & Co’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-6,571
| Closed | -$358K | – | 152 |
|
|
2022
Q2 | $358K | Buy |
6,571
+2,352
| +56% | +$130K | 0.01% | 135 |
|
|
2022
Q1 | $230K | Hold |
4,219
| – | – | 0.01% | 153 |
|
|
2021
Q4 | $233K | Hold |
4,219
| – | – | 0.01% | 157 |
|
|
2021
Q3 | $202K | Hold |
4,219
| – | – | 0.01% | 154 |
|
|
2021
Q2 | $210K | Sell |
4,219
-2,680
| -39% | -$129K | 0.01% | 149 |
|
|
2021
Q1 | $308K | Sell |
6,899
-19,844
| -74% | -$901K | 0.01% | 136 |
|
|
2020
Q4 | $1.23M | Buy |
26,743
+4,016
| +18% | +$184K | 0.04% | 97 |
|
|
2020
Q3 | $1.07M | Sell |
22,727
-55,745
| -71% | -$2.79M | 0.04% | 96 |
|
|
2020
Q2 | $4M | Sell |
78,472
-21,388
| -21% | -$1.1M | 0.16% | 71 |
|
|
2020
Q1 | $4.73M | Sell |
99,860
-800
| -0.8% | -$42.7K | 0.23% | 65 |
|
|
2019
Q4 | $5.91M | Sell |
100,660
-550,328
| -85% | -$30.6M | 0.24% | 63 |
|
|
2019
Q3 | $34.7M | Buy |
650,988
+32,776
| +5% | +$1.69M | 1.48% | 31 |
|
|
2019
Q2 | $30.9M | Buy |
618,212
+54,140
| +10% | +$2.72M | 1.33% | 37 |
|
|
2019
Q1 | $29.5M | Buy |
564,072
+184,320
| +49% | +$9.21M | 1.3% | 39 |
|
|
2018
Q4 | $18.1M | Buy |
379,752
+369,480
| +3,597% | +$18.2M | 0.91% | 53 |
|
|
2018
Q3 | $516K | Sell |
10,272
-509
| -5% | -$25.9K | 0.02% | 118 |
|
|
2018
Q2 | $543K | Buy |
10,781
+69
| +0.6% | +$3.48K | 0.03% | 117 |
|
|
2018
Q1 | $523K | Hold |
10,712
| – | – | 0.02% | 118 |
|
|
2017
Q4 | $475K | Sell |
10,712
-4,874
| -31% | -$225K | 0.02% | 120 |
|
|
2017
Q3 | $791K | Buy |
15,586
+100
| +0.6% | +$5.07K | 0.04% | 110 |
|
|
2017
Q2 | $835K | Buy |
15,486
+1,120
| +8% | +$59.7K | 0.04% | 106 |
|
|
2017
Q1 | $757K | Buy |
14,366
+2,256
| +19% | +$114K | 0.04% | 105 |
|
|
2016
Q4 | $583K | Buy |
12,110
+400
| +3% | +$19.8K | 0.03% | 113 |
|
|
2016
Q3 | $631K | Buy |
11,710
+1,066
| +10% | +$58.4K | 0.03% | 110 |
|
|
2016
Q2 | $577K | Buy |
10,644
+768
| +8% | +$40.5K | 0.03% | 108 |
|
|
2016
Q1 | $501K | Sell |
9,876
-1,252
| -11% | -$62.4K | 0.03% | 107 |
|
|
2015
Q4 | $561K | Buy |
11,128
+200
| +2% | +$10.2K | 0.03% | 116 |
|
|
2015
Q3 | $525K | Sell |
10,928
-484
| -4% | -$25.2K | 0.03% | 120 |
|
|
2015
Q2 | $594K | Sell |
11,412
-1,212
| -10% | -$68.2K | 0.03% | 121 |
|
|
2015
Q1 | $728K | Sell |
12,624
-160
| -1% | -$9.17K | 0.04% | 115 |
|
|
2014
Q4 | $683K | Sell |
12,784
-728
| -5% | -$40.7K | 0.03% | 119 |
|
|
2014
Q3 | $776K | Buy |
13,512
+1,552
| +13% | +$95.1K | 0.04% | 121 |
|
|
2014
Q2 | $800K | Buy |
11,960
+984
| +9% | +$66.6K | 0.04% | 115 |
|
|
2014
Q1 | $733K | Sell |
10,976
-213,880
| -95% | -$14.5M | 0.04% | 113 |
|
|
2013
Q4 | $15M | Sell |
224,856
-45,092
| -17% | -$2.92M | 0.73% | 73 |
|
|
2013
Q3 | $16.9M | Buy |
269,948
+3,528
| +1% | +$227K | 0.87% | 64 |
|
|
2013
Q2 | $16.6M | Buy |
+266,420
| New | +$16.9M | 0.89% | 55 |
|
Other funds holding GSK
Bowen Hanes & Co's GSK Position: Q3 2022 in Review
Bowen Hanes & Co sold out of GSK (GSK) in Q3 2022, closing a stake of 6,571 shares — an estimated $358K sold.
Bowen Hanes & Co first reported a position in GSK in Q2 2013 and held it in 37 quarters. The position peaked at $34.7M in Q3 2019. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.
- Bowen Hanes & Co reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
- Bowen Hanes & Co sold 6,571 GSK shares in Q3 2022, an estimated $358K.
- Bowen Hanes & Co first reported a position in GSK in Q2 2013 and held it in 37 quarters.
- Bowen Hanes & Co's GSK position peaked at $34.7M in Q3 2019.
- 742 funds tracked by Wall St. Rank held GSK as of Q3 2022.
Based on Bowen Hanes & Co's 13F filing for Q3 2022, filed 14 Nov 2022.